Jazz Pharmaceuticals plc — Director's Dealing 2022

May 11, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2022-05-09

Reporting Person: Carr Patricia (SVP, Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-09	Ordinary Shares	S	1056	$148.9281	Disposed	7240	Direct
2022-05-09	Ordinary Shares	S	11	$150.49	Disposed	7229	Direct
2022-05-10	Ordinary Shares	S	273	$144.1792	Disposed	6956	Direct
2022-05-11	Ordinary Shares	S	722	$147.5139	Disposed	6234	Direct

Footnotes

F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $148.92 to $149.91 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.11 to $144.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $147.51 to $147.65. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.